Home Cart Sign in  
Chemical Structure| 135459-87-9 Chemical Structure| 135459-87-9

Structure of Strontium Ranelate
CAS No.: 135459-87-9

Chemical Structure| 135459-87-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Strontium ranelate stimulates the calcium sensing receptors (CaSR) and leads to the differentiation of pre-osteoblast to osteoblast which increases the bone formation.

Synonyms: S12911; Distrontium renelate; Strontium Ranelate, trade mane: Protelos or Proto.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Strontium Ranelate

CAS No. :135459-87-9
Formula : C12H6N2O8SSr2
M.W : 513.49
SMILES Code : N#CC1=C(N(CC([O-])=O)CC([O-])=O)SC(C([O-])=O)=C1CC([O-])=O.[Sr+2].[Sr+2]
Synonyms :
S12911; Distrontium renelate; Strontium Ranelate, trade mane: Protelos or Proto.
MDL No. :MFCD09038742

Safety of Strontium Ranelate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302+H312+H332
Precautionary Statements:P280

Related Pathways of Strontium Ranelate

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MC3T3-E1 cells 0.01, 0.1, 1.0 mg/ml 1 day, 4 days, 7 days Enhanced cell adhesion, proliferation, alkaline phosphatase activity, collagen secretion and extracellular matrix mineralization deposition Regen Biomater. 2020 Nov 28;8(1):rbaa043
Rat bone mesenchymal stem cells (BMSCs) 0.25 mM 14 days To investigate the effect of SrR on chondrogenic differentiation of BMSCs, results showed that 0.25 mmol/L SrR significantly promoted chondrogenesis and increased the expression of Sox-9, Col-II, and aggrecan. Stem Cell Res Ther. 2021 May 20;12(1):296

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Femoral condyle cartilage defect model Local administration (GelMA + SrR-loaded silica nanospheres) 2.0 mM Single administration, lasting for 3 months To evaluate the effect of local SrR release on cartilage regeneration, results showed that SrR significantly promoted cartilage regeneration and reduced the activation level of β-catenin. Stem Cell Res Ther. 2021 May 20;12(1):296
Sprague Dawley rats Medial meniscal tear (MMT) induced osteoarthritis model Gavage 625 or 1800 mg/kg/d Once daily for 3 or 6 weeks To investigate whether strontium ranelate could attenuate cartilage degeneration and subchondral bone remodeling in osteoarthritis. The high-dose (1800 mg·kg-1·d-1) significantly attenuated cartilage matrix and chondrocyte loss, decreased chondrocyte apoptosis, improved SOX9 expression, and significantly improved subchondral bone microarchitecture indices, TMD, mineral-to-collagen ratio, and intrinsic mechanical properties. The low-dose (625 mg·kg-1·d-1) did not significantly change all detection indices of cartilage and bone at both 3 and 6 weeks. Acta Pharmacol Sin. 2013 Mar;34(3):393-402
Swiss male mice Healthy growing mice Drinking water 7.78 mM Free access daily for 8 weeks To compare the effects of strontium ranelate and strontium chloride on bone microarchitecture in mice. Results showed that both strontium ranelate and strontium chloride significantly increased bone volume percentage (BV/TV), trabecular number (Tb.N), and trabecular thickness (Tb.Th), and decreased trabecular separation (Tb.Sp). No significant differences were observed between the effects of the two strontium salts on bone microarchitecture. Nutrients. 2023 Dec 27;16(1):91

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02637180 - Completed - Greece ... More >> NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, MEDICAL SCHOOL, 2nd DEPARTMENT OF ORTHOPAEDIC SURGERY Athens, Attiki, Greece, 14233 Democritus University of Thrace, School of Medicine, Department of Orthopaedic Surgery Alexandroupolis, Evros, Greece, 68100 Orthopaedic Department, Faculty of Medicine, School of Health Sciences, University of Thessalia Larissa, Greece, 41110 Aristotle University of Thessaloniki, 3rd University Orthopaedic Department, Papageorgiou General Hospital Thessaloniki, Greece, 56403 Less <<
NCT00409032 Osteoporosis Phase 2 Completed - Denmark ... More >> PhaseOneTrials Hvidovre, Denmark, 2650 Odense University Hospital Odense, Denmark, 5000 United Kingdom Medinova Clinic Northwood, Middlesex, United Kingdom Synexus Wales Clinical Research Centre Cardiff, United Kingdom, CF14 5GJ Synexus Scotland Clinical Research Centre Glasgow, United Kingdom, G81 2DR Synexus Limited Reading Clinical Research Centre Reading, United Kingdom, RG2 7AG University of Sheffield Sheffield, United Kingdom, S5 7AU Synexus Crosby Clinical Research Centre Waterloo, United Kingdom, L22 0LG Synexus Wigan Clinical Research Centre Wigan, United Kingdom, WN1 1XX Less <<
NCT00239629 Postmenopausal Osteoporosis Phase 4 Completed - Czech Republic ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Prague, Czech Republic, 128 21 Germany For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hamburg, Germany, 20354 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Heidelberg, Germany, 69120 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Magdeburg, Germany, D-39110 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Vogelsang, Germany, 39245 Greece For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Kifissia, Greece, 145 61 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Thessaloniki, Greece, 56429 Israel For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Haifa, Israel, 31096 Mexico For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Guadalajara, Mexico, 44670 Spain For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Barcelona, Spain, 08025 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Madrid, Spain, 28041 Less <<
NCT00479037 Osteoporosis Phase 4 Completed - Denmark ... More >> Nycomed Roskilde, Denmark, 4000 Less <<
NCT00479037 - Completed - -
NCT01222026 Primary Hyperparathyroidism ... More >> Osteopenia Osteoporosis Less << Phase 4 Completed - Austria ... More >> Medical University Vienna, General Hospital Vienna (AKH Wien) Vienna, Austria, 1090 Less <<
NCT01544894 Postmenopausal Osteoporosis ... More >> Compliance Less << Phase 4 Completed - Spain ... More >> Hospital Universitario Dr Peset Valencia, Spain, 46017 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.95mL

0.39mL

0.19mL

9.74mL

1.95mL

0.97mL

19.47mL

3.89mL

1.95mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories